AET BioTech and BioXpress Therapeutics have signed a research deal for the development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
Under the agreement, both the companies will be responsible for the development, registration and manufacture of the biosimilar that leverages BioXpress technology.
AET BioTech managing director Dr Harm Peters said the partnership will unite the technical and commercial strengths behind the Adalimumab biosimilar.
"The cooperation with BioXpress on our initial project is a key step in AET BioTech's mission to bring European quality biosimilar drugs to markets worldwide at fair prices," Dr Peters added.
AET BioTech is responsible for providing further investment in the biosimilar and also for future commercialisation of the product.
Non-clinical and clinical guidelines outlined in the European Medicines Agency's guideline on similar biological medicinal products containing monoclonal antibodies, will be followed in the development of Adalimumab biosimilar.
The product will also undergo ethical and comprehensive analytical and clinical comparison to ensure the similarity.
